



| Report Number: | 22-015800/D006.R000 |
|-----------------|---------------------|
| Report Date: | 01/04/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 12/28/22 16:43 |

_ _ _ _ _ _

| Customer: | IHC LLC |
|-------------------|---------------------|
| Product identity: | D8 - Lemon Meringue |
| Client/Metrc ID: | |
| Laboratory ID: | 22-015800-0015 |

Summary

| Analyte | Result (%) | | | |
|---------|------------|---|------------------|------------------------|
| ∆8-THC | 30.2 | Δ8-THC CBD-A | CBD-Total | 9.49% |
| CBD-A | 9.76 | CBD-A | | |
| CBD | 0.930 | CBG-A | THC-Total | <loq< td=""></loq<> |
| CBG-A | 0.164 | Δ8-THCV | | |
| ∆8-THCV | 0.112 | • CBG | (Reported in per | rcent of total sample) |
| CBG | 0.0798 | CBDV-A | | |
| CBDV-A | 0.0723 | • CBT | | |
| CBT | 0.0483 | CBC-A | | |
| CBC-A | 0.0429 | • CBC | | |
| CBC | 0.0329 | | | |

Page 1 of 9
Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made.
Testing in accordance with: OAR 333-007-0430



IHC LLC

.

No 15.2 °C

Client

825 NW 16th Ave Portland Oregon 97209

D8 - Lemon Meringue

22-015800-0015

United States of America (USA)

Customer:

Product identity:

Client/Metrc ID:

Sample Date:

Laboratory ID:

Temp:

Evidence of Cooling:

Relinquished by:

12423 NE Whitaker Way Portland, OR 97230 503-254-1794



| 22-015800/D006.R000 |
|---------------------|
| 01/04/2023 |
| OR100028 |
| |
| 12/28/22 16:43 |
| |



Sample Results

| Potency | Method: J AOAC 201 | 5 V98-6 (mod) ^p | Units % | Batch: 2300022 | Analyze: 12/30/22 | 10:46:00 P |
|--------------------|--------------------|----------------------------|---------|----------------|-------------------|--|
| Analyte | As Dry | | lotes | | | |
| | Received weig | ht | | | | 单 Δ8-THC |
| CBC | 0.0329 | 0.0292 | | | | CBD-A |
| CBC-A | 0.0429 | 0.0292 | | | | CBD |
| CBC-Total | 0.0705 | 0.0547 | | | | CBG-A Δ8-THCV |
| CBD | 0.930 | 0.0292 | | | | CBG |
| CBD-A | 9.76 | 0.292 | | | | CBDV-A |
| CBD-Total | 9.49 | 0.285 | | | | CBT |
| CBDV | < LOQ | 0.0292 | | | | CBC-A |
| CBDV-A | 0.0723 | 0.0292 | | | | CBC |
| CBDV-Total | 0.0627 | 0.0544 | | | | |
| CBE | < LOQ | 0.0292 | | | | |
| CBG | 0.0798 | 0.0292 | | | | |
| CBG-A | 0.164 | 0.0292 | | | | |
| CBG-Total | 0.224 | 0.0544 | | | | |
| CBL | < LOQ | 0.0292 | | | | |
| CBL-A | < LOQ | 0.0292 | | | | |
| CBL-Total | < LOQ | 0.0547 | | | | |
| CBN | < LOQ | 0.0292 | | | | |
| CBT | 0.0483 | 0.0292 | | | | |
| Δ10-THC | < LOQ | 0.0292 | | | | |
| ∆8-THC | 30.2 | 0.292 | | | | |
| ∆8-THCV | 0.112 | 0.0292 | | | | |
| ∆9-THC | < LOQ | 0.0292 | | | | |
| exo-THC | < LOQ | 0.0292 | | | | |
| THC-A | < LOQ | 0.0292 | | | | |
| THC-Total | < LOQ | 0.0547 | | | | |
| THCV | < LOQ | 0.0292 | | | | |
| THCV-A | < LOQ | 0.0292 | | | | |
| THCV-Total | < LOQ | 0.0544 | | | | |
| Total Cannabinoids | 41.4 | | | | | |

www.columbialaboratories.com

Page 2 of 9

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

Testing in accordance with: OAR 333-007-0430





Report Number: 22-015800/D006.R000 **Report Date:** 01/04/2023 **ORELAP#:** OR100028 Purchase Order: **Received:** 12/28/22 16:43

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

^b = ISO/IEC 17025:2017 accredited method.

Units of Measure

% = Percentage of sample

% wt = $\mu g/g$ divided by 10,000

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 3 of 9

Test results relate only to the parameters tested and to the samples as received by the requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made





22-015800/D006.R000 **Report Number: Report Date:** 01/04/2023 **ORELAP#:**

Purchase Order: Received:

OR100028

12/28/22 16:43

| | | | 1 | | | | calist | it Kng | LIBER | d . | | | | | Contractor and the | |
|---|--------|---------|------------------|--------------------------------------|-----------|--------------------|----------------------------|-----------|-----------------|------------------------------|---------------|------------|--------|--|--|---|
| Ine Hemp Collect Contact: kyle@thenempcol Street: 431 NW Flanders st. city: Portland State: @ tmail #enuite: dropbox (IHI #h: (b) 5005104 (IHI #h: (b) 5005104 (IHI #h: (b) 5005104 (IHI #h: (b) 5005104 (IHI |)+ 2ip | 97209 | -08.59 compareds | calidas Melu-Araidum - 379 compounds | | erenta. | oststern & Whiter Activity | | Years and Model | Non-2-call and Total Colliam | 44 | | | Projec Pro Custorin T Report to Termerou | t Number: ect Werner: inporting: of State - [] Mi of State - [] Mi | ETRIC or [1] Other: Subinets Day Standard Turnaround Businets Day Roth Tornaround* Dusinees Day Rush Tantaround* Check for accelebility |
| 0 0 Geet Sample Hentification 010307LIRVAP200 PK | Date | Circe. | Peptides- | Festicide M | × Potency | Presidual Solventa | Weithern R | Terperars | Micro: Yea | Mun. A.O. | Hearly Metals | Mycotowins | Other: | Sampled Sample Type 1 | Weight (UVIS) | Comments/Metric ID |
| 010307LIRVAP200_LIa | ma | | - | - | x | | - | - | 1.1 | - | | - | | C | | |
| 010307LIRVAP200_OG | K | | - | - | x | | - | | | - | - | | | C | | |
| 0103LIRVAP200_WB | - | | | | x | | | | | | - | | | C | | |
| 0103LIRVAP200_Lava | | | | | x | | 1 | | | - | | | - 3 | C | | |
| 0103LIRVAP200_PB | | | | | x | | | | | | | | | G | | |
| 0103LIRVAP200_SP | | | | | × | | - | | | | | | | C | | |
| 0103LIRVAP200_SG | | | | | x | | | | | | | | 3 | C | | |
| 0103LIRVAP200_OG | | | | | x | | | | | | | | | C | | |
| 0 0103LIRVAP200_STs | | | | - | x | | | | | | | | | C | | e |
| Bolingated By: | itute | Time | | | h | sol-st | By: | | | Ď | Ar . | n | 00 | | | Call Use Only |
| (yle Farook | 12/27 | 12:00 F | | | 1 | A:c | | | | 12- | 21 | 164 | 34 | Exidence Sample In El Cash J | griad condition | O'(C) Colord sirop Tes D No - Tenip (*C): zz (C) (*C) No CC C) Note: |

E-Sample Type Cades: Vegetation (V) / holeiex (S) ; Extract/Concentrate (C); Texture/Topical (I); EXELs (E); Beverage (II)

Surgice coloured to Colourie Colouries Colouries Colouries Colouries controls to an aproximative activities in constants with the control stress drivers and add with the CCC As agoing "Anhyaetheddy" year or aproximative inter-12422 AR WRITEN WAY #1(\$800,254-1784) Rec (\$850,254-1452

Partient, CR #7,130

intellimitationitia televisitation peris

Page of ______

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

| Columbia LABORATORIES A Tentamus Company Hen | | | | | | inab | Porti 50 is Us hain | sabl | , OF 254- 1, 54 1, | ody | 230 4 ect / Rec 24/20 | Fini | | | Ri O Pi Ri oducts | eport Nu eport Da RELAP# urchase eceived | ate: t: Order: : | 22-015800/D006.R0 01/04/2023 OR100028 12/28/22 16:43 |
|--|-------------------------|----------------------|-------------------------------------|------------------|-----------|------------------------|------------------------------|---------------------|---|----------|-----------------------------------|-----------------|---------------------|--|--|--|--|---|
| | | | | | | | | inalys | is Rev | Ueste | d | | | | | 0 Number | | |
| Dempany: The Hemp Collect Context: kyle@thehempcollect.com Street: 431 NW Flanders st. Cay Portland Stee OF 26: 97209 RE Email Results: dropbox (IHC) Ph: (61) 008164 Px Results: () Stilling (1 different); joel%thehempcollect.com | | a - DR 35 comparatis | diste Mutti-Residue - 379 compounds | | Solvertii | sture & Water Astivity | | Icro: Years and MeM | to: E.O.N. and Takal Colfform | and A | 100 | | Eustone Report t | (ect Name Naporting o State - [] M mil time: 12 [] | AETRC or 🗇 (5 Business Da 3 Business Da | Dher :y Standard Turearound y Resh Tursaround* y Resh Tursaround* wilsh Dertaround* | | |
| | d Semple Identification | | Time | Pestidies | Fedicida | Pilence | Inddund | Mointers | Partners of | Micros V | MICHOLE. | Marriel Warrely | Myconomy | men | Serople Type I | Weight (Units) | | Comments/Metro ID |
| 2.1.1.2.1.2.1 | 030506LIRVAP_T | 522 | | | | х | | | | | | | | | 0 | | and the second sec | \$ \$6 & \$7. Alternate |
| 24 - A C C C C C C C C C C C C C C C C C C | 030506LIRVAP_F | 100 00 | | | | х | | | | | | | | | C | | client na | ine. |
| 2.2.52 | 030506LIRVAP_G | 7 | | | | x | | | | | | | | | C | | Vesl Oils | 8 |
| 10000 | Sour Pineapple | | | | | х | | | | | | | | | V | | | |
| S | Lemon Meringue | | | | | х | | | | | | | | | V | | 1 | |
| 2. 20.0 | ouble - SSH | | | | | X | | | | | | | | | V | | | |
| / DB D | ouble - SHH | | | | | X | | | | | | | | | V | | | |

12423 W Withher Way Fortheet, UK 85280

Kyle Farook

Enlinquented Re

Time

12:00 F

Done

12/27

Supply adopted to Coloring Laboratories with stating to patronic constitute using

8 盲 10

> 7: (999) 254 (2947 Nov: (503) 254 (452 rich bereturned him **Info@Eczie**

1 - Sample Type Codes: Vegetation (V) ; Nointes (S) ; Extract/Concentrate (C) ; Texture/Topical (T) ; Edible (C) ; Beerrage (R)

Received By:

AC

Gate.

Tares.

16:34

where constructs is accordance with the convectories of service summation with the CON. By signing "ArbayekdiseThy" (

12.27 1200

C Shipped Via:

Profing storage:

n or againing a dear i Page____rd_

La9 Use Only!

Evidence of cooling: [] Yes | Bitto - Temp (*C): 15-2

Sample in good condition: 1 Tim | D No. Cliceth | Clickack | ClicC | CliMet:

or III Clant drop

Page 5 of 9 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
prior arrangements have been made.





| Report Number: | 22-015800/D006.R000 |
|-----------------|---------------------|
| Report Date: | 01/04/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 12/28/22 16:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| J AOAC 2015 V98 | -6 | | La | Batch ID: 2300022 | | | | | | | | | |
|------------------|-----------|--|-------|-------------------|-------|------|--------|------------|-------|--|--|--|--|
| Laboratory Contr | ol Sample | | | | | | | | | | | | |
| Analyte | LCS | Result | Spike | Units | % Rec | L | .imits | Evaluation | Notes | | | | |
| CBDVA | 2 | 0.0329 | 0.034 | % | 97.6 | 80.0 | - 120 | Acceptable | | | | | |
| CBDV | 2 | 0.0348 | 0.037 | % | 94.8 | 80.0 | - 120 | Acceptable | | | | | |
| CBE | 2 | 0.0319 | 0.035 | % | 90.0 | 80.0 | - 120 | Acceptable | | | | | |
| CBDA | 1 | 0.0349 | 0.034 | % | 101 | 90.0 | - 110 | Acceptable | | | | | |
| CBGA | 1 | 0.0347 | 0.034 | % | 101 | 80.0 | - 120 | Acceptable | | | | | |
| CBG | 1 | 0.0353 | 0.035 | % | 102 | 80.0 | - 120 | Acceptable | | | | | |
| CBD | 1 | 0.0393 | 0.035 | % | 113 | 90.0 | - 110 | Acceptable | Q | | | | |
| THCV | 2 | 0.0334 | 0.035 | % | 95.1 | 80.0 | - 120 | Acceptable | | | | | |
| d8THCV | 2 | 0.0332 | 0.036 | % | 93.4 | 80.0 | - 120 | Acceptable | | | | | |
| FHCVA | 2 | 0.0308 | 0.033 | % | 93.6 | 80.0 | - 120 | Acceptable | | | | | |
| CBN | 1 | 0.0372 | 0.036 | % | 104 | 80.0 | - 120 | Acceptable | | | | | |
| exo-THC | 2 | 0.0349 | 0.034 | % | 102 | 80.0 | - 120 | Acceptable | | | | | |
| d9THC | 1 | 0.0395 | 0.037 | % | 106 | 90.0 | - 110 | Acceptable | | | | | |
| d8THC | 1 | 0.0344 | 0.036 | % | 95.6 | 90.0 | - 110 | Acceptable | | | | | |
| CBL | 2 | 0.0333 | 0.033 | % | 100 | 80.0 | - 120 | Acceptable | | | | | |
| d10THC | 1 | NA | 0.033 | % | NA | 80.0 | - 120 | Acceptable | Q6 | | | | |
| CBC | 2 | 0.0342 | 0.036 | % | 94.1 | 80.0 | - 120 | Acceptable | | | | | |
| ГНСА | 1 | 0.0349 | 0.034 | % | 103 | 90.0 | - 110 | Acceptable | | | | | |
| CBCA | 2 | 0.0314 | 0.034 | % | 91.4 | 80.0 | - 120 | Acceptable | | | | | |
| CBLA | 2 | 0.0327 | 0.035 | % | 93.6 | 80.0 | - 120 | Acceptable | | | | | |
| CBT | 2 | 0.0354 | 0.036 | % | 97.3 | 80.0 | - 120 | Acceptable | | | | | |
| Method Blank | | | | | | | | | | | | | |
| Analyte | | lesult | LOQ | | Units | | .imits | Evaluation | Notes | | | | |
| CBDVA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBDV | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBE | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBDA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBGA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBG | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBD | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| THCV | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| d8THCV | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| THCVA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBN | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| exo-THC | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| d9THC | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| d8THC | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBL | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| 10THC | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBC | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| THCA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| CBCA | | <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<> | 0.03 | | % | | 0.03 | Acceptable | | | | | |
| | | | | | | |).03 | Acceptable | | | | | |
| CBLA CBT | | <loq <loq< td=""><td>0.03</td><td></td><td>%</td><td></td><td>0.03</td><td>Acceptable</td><td></td></loq<></loq | 0.03 | | % | | 0.03 | Acceptable | | | | | |

s ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure: % - Percent

Page 6 of 9 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made.
Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-015800/D006.R000 |
|-----------------|---------------------|
| Report Date: | 01/04/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 12/28/22 16:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| | | | La | boratory | Quality Cont | rol Results | | | | | | | |
|-------------------|---|---|------|----------|--------------|----------------|------------|-------|--|--|--|--|--|
| J AOAC 2015 V98-6 | | | | | Bat | ch ID: 2300022 | | | | | | | |
| Sample Duplicate | Sample ID: 22-015800-0014 | | | | | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | | | | | |
| CBDVA | 0.0727 | 0.0732 | 0.03 | % | 0.701 | < 20 | Acceptable | | | | | | |
| CBDV | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBE | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBDA | 9.67 | 9.58 | 0.03 | % | 0.998 | < 20 | Acceptable | | | | | | |
| CBGA | 0.163 | 0.166 | 0.03 | % | 2.00 | < 20 | Acceptable | | | | | | |
| CBG | 0.0752 | 0.0747 | 0.03 | % | 0.602 | < 20 | Acceptable | | | | | | |
| CBD | 0.901 | 0.914 | 0.03 | % | 1.39 | < 20 | Acceptable | | | | | | |
| THCV | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| d8THCV | 0.111 | 0.111 | 0.03 | % | 0.546 | < 20 | Acceptable | | | | | | |
| THCVA | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBN | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| exo-THC | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| d9THC | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| d8THC | 29.9 | 29.9 | 0.03 | % | 0.00552 | < 20 | Acceptable | | | | | | |
| CBL | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| d10THC | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBC | 0.0325 | 0.0342 | 0.03 | % | 5.00 | < 20 | Acceptable | | | | | | |
| THCA | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBCA | 0.0411 | 0.0434 | 0.03 | % | 5.50 | < 20 | Acceptable | | | | | | |
| CBLA | <loq< td=""><td><loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.03</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.03 | % | NA | < 20 | Acceptable | | | | | | |
| CBT | 0.0502 | 0.0498 | 0.03 | % | 0.902 | < 20 | Acceptable | | | | | | |

ND - None Detected at or above MRL RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

Page 7 of 9 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made.
Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-015800/D006.R000 |
|-----------------|---------------------|
| Report Date: | 01/04/2023 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 12/28/22 16:43 |



Page 8 of 9
Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made.
Testing in accordance with: OAR 333-007-0430





22-015800/D006.R000 **Report Number: Report Date:** 01/04/2023 **ORELAP#:** OR100028 **Purchase Order:** 12/28/22 16:43 **Received:**

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |

Page 9 of 9 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan
unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless
prior arrangements have been made.
Testing in accordance with: OAR 333-007-0430

SD230329-008 page 1 of 2

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

sample 03DTST224_AMBER_D8 Distillate

DPharmLabs

Sample ID SD230329-008 (71349) Matrix Concentrate (Inhalable Cannabis Good)

Tested for The Hemp Collect Sampled -Received Mar 28, 2023 Analyses executed CAN+, RES, MIBIG, MTO, PES, HME, FVI

Reported Apr 05, 2023

Laboratory note: The estimated concentration of the unknown peak in the sample is 660% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC, (+)d8-THC is a different compound from the main (-)d8-THC cannobinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PhormLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be 94.56%.

CAN+ - Cannabinoids Analysis

Analyzed Apr 04, 2023 | Instrument HPLC-VWD | Method SOP-001 The expanded Uncertainty of the Cannabinoid analysis is approximately **#.806%** at the 95% Confidence Level

| Indy of many of the mark of the | The expanded offeer taining of the cannobiola analysis is approximately 2.000% at the 75% connactice zever | | | | |
|---|--|-------|------|-------|--------|
| Cannabidolic Acid (CBDA) 0.001 0.16 ND ND Cannabigerol Acid (CBGA) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabidol (CBD) 0.001 0.16 ND ND Cannabidol (CBN) 0.001 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (AS-THC) 0.002 0.16 ND ND Cannabigoral (CBC) 0.001 0.16 ND ND Cannabigoral (CBC) 0.002 0.16 ND ND Cannabigoral (CBC) 0.001 | Analyte | | | | |
| Cannabigerol Acid (CBGA) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigorol (CBG) 0.001 0.16 ND ND Cannabigorol (CBO) 0.001 0.16 ND ND Cannabinol (CBN) 0.001 0.16 ND ND Cannabinol (A9-THC) 0.003 0.16 UI UI AB-tetrahydrocannabinol (A9-THC) 0.002 0.16 ND ND Cannabicyclo (CBL) 0.002 0.16 ND ND Cannabinol (A9-THC) 0.002 0.16 ND ND Cannabinol (CBL) 0.002 0.16 ND ND Cannabinolic Acid (THCA) 0.001 0.16 ND ND Cannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa* 0.877 + A9THC) ND ND ND Total CBC (EBGa* 0.877 + CBB) <t< td=""><td>Cannabidivarin (CBDV)</td><td>0.039</td><td>0.16</td><td>ND</td><td>ND</td></t<> | Cannabidivarin (CBDV) | 0.039 | 0.16 | ND | ND |
| Cannabigerol (CBG) 0.001 0.16 ND ND Cannabigerol (CBG) 0.001 0.16 ND ND Tetrahydrocannabivorin (THCV) 0.001 0.16 ND ND Cannabilo (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ9-THC) 0.002 0.16 ND ND Cannabilo (CBL) 0.002 0.16 ND ND Cannabilo (THCA) 0.001 0.16 ND ND Cannabilo (CBL) 0.001 0.16 ND ND Cannabilo (CBL) 0.001 0.16 ND ND Tetrahydrocannabinol (AS-TTHCASTT + ΔSTTHC) ND ND ND Total THC (THCa* 0.877 + ΔSTHC) Y | Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabidi (CBD) 0.001 0.16 ND ND Tetrahydrocannabivarin (THCV) 0.001 0.16 ND ND Cannabidiol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ8-THC) 0.004 0.16 94.56 945.60 Cannabidiol (CBL) 0.002 0.16 ND ND Cannabidoniol (Δ8-THC) 0.002 0.16 ND ND Cannabidol (CBL) 0.001 0.16 ND ND Cannabidol (CBL) 0.001 0.16 ND ND Total THC (THCa * 0.877 + Δ9THC + Δ | Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocannabivarin (THCV) 0.001 0.16 ND ND Cannabinol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocannabinol (Δ8-THC) 0.004 0.16 94.56 945.60 Cannabicyclol (CBL) 0.002 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Cannabicyclol (CBL) 0.001 0.16 ND ND Total THC (THca ^{0.0877 + Δ971+C Δ97} | Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabinol (CBN) 0.001 0.16 ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 U1 U1 Δ8-tetrahydrocannabinol (Δ9-THC) 0.004 0.16 94.56 945.60 Cannabinol (Δ9-THC) 0.002 0.16 ND ND Δ8-tetrahydrocannabinol (Δ9-THC) 0.002 0.16 ND ND Cannabichomene (CBL) 0.002 0.16 ND ND Cannabichomene (CBC) 0.001 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa*0.877 + Δ9THC) ND ND ND Total THC (THCa*0.877 + Δ9THC + Δ8THC) 94.56 945.60 Total CBG (EBGa*0.877 + CB) ND ND Total CBG (EBGa*0.877 + CB) ND ND | Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| Tetrahydrocanabinol (Δ9-THC) 0.003 0.16 UI UI Δ8-tetrahydrocanabinol (Δ9-THC) 0.004 0.16 94.56 945.60 Canabicyclol (CBL) 0.002 0.16 ND ND Canabichromene (CBC) 0.002 0.16 ND ND Tetrahydrocanabinol (Ad-THCA) 0.001 0.16 ND ND Total THC (THCa ⁺ 0.877 + Δ9THC) ND ND ND Total THC (THCa ⁺ 0.877 + Δ9THC + Δ8THC) 94.56 945.60 ND Total CBD (CBDa ⁺ 0.877 + Δ9THC + Δ8THC) ND ND ND Total CBG (CBDa ⁺ 0.877 + CBG) ND ND ND | Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Ab-tetra/glarcannabinol (Ab-THC) 0.004 0.16 94.56 945.60 Cannabicyclol (CBL) 0.002 0.16 ND ND Cannabicyclol (CBC) 0.002 0.16 ND ND Tetra/glarcannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa * 0.877 + A9THC) ND ND ND Total CBD (CBDa* 0.877 + A9THC + A8THC) 94.56 94.56 Total CBD (CBDa* 0.877 + CBD) ND ND Total CBG (CBGa* 0.877 + CBG) ND ND | Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Cannabicyclol (CBL) 0.002 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa ° 0.877 + 49THC) ND ND ND Total THC + 48THC (THCa ° 0.877 + 49THC + 48THC + 48T | Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | UI | UI |
| Cannabichromene (CBC) 0.002 0.16 ND ND Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa ^{0.0877 +} A9THc) ND ND ND Total THC + A8THC (THCa ^{0.0877 +} A9THc + A8THc) 94.56 945.60 Total CBC (BBGa ^{0.0877 +} CBD) ND ND Total CBC (CBGa ^{0.0877 +} CBC) ND ND | Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 94.56 | 945.60 |
| Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND Total THC (THCa * 0.877 + Δ9THc) ND ND ND Total THC + Δ8THC (THCa * 0.877 + Δ9THc + Δ8THc) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Cannabicyclol (CBL) | 0.002 | 0.16 | ND | ND |
| Total THC (THCa * 0.877 + Δ9THc) ND ND Total THC + Δ8THC (THCa * 0.877 + Δ9THc + Δ8THc) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Cannabichromene (CBC) | 0.002 | 0.16 | ND | ND |
| Total THC + A&THC (THCa * 0.877 + AØTHC + A&THC) 94.56 945.60 Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Total CBD (CBDa * 0.877 + CBD) ND ND Total CBG (CBGa * 0.877 + CBG) ND ND | Total THC (THCa * 0.877 + Δ9THC) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) ND ND | Total THC + Δ 8THC (THCa * 0.877 + Δ 9THC + Δ 8THC) | | | 94.56 | 945.60 |
| | Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total Cannabinoids 94.56 945.60 | Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| | Total Cannabinoids | | | 94.56 | 945.60 |

HME - Heavy Metals Detection Analysis

Analyzed Apr 04, 2023 | Instrument ICP/MSMS | Method SOP-005

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|--------------|-------------|-------------|----------------|---------------|--------------|-------------|-------------|----------------|---------------|
| Arsenic (As) | 0.0002 | 0.0005 | ND | 0.2 | Cadmium (Cd) | 3.0e-05 | 0.0005 | ND | 0.2 |
| Mercury (Hg) | 1.0e-05 | 0.0001 | ND | 0.1 | Lead (Pb) | 1.0e-05 | 0.00125 | ND | 0.5 |

MIBIG - Microbial Testing Analysis

Analyzed Mar 31, 2023 | Instrument qPCR and/or Plating | Method SOP-007

| Analyte | Result CFU/g | Limit | Analyte | Result CFU/g | Limit |
|--|-----------------|---------------|---------------------|-----------------|---------------|
| Shiga toxin-producing Escherichia Coli | ND | ND per 1 gram | Salmonella spp. | ND | ND per 1 gram |
| Aspergillus fumigatus | ND | ND per 1 gram | Aspergillus flavus | ND | ND per 1 gram |
| Aspergillus niger | ND | ND per 1 gram | Aspergillus terreus | ND | ND per 1 gram |

MTO - Mycotoxin Testing Analysis

Analyzed Apr 04, 2023 | Instrument LC/MSMS | Method SOP-004

| Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg | Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg (ppb) | Limit ug/kg |
|--------------|--------------|--------------|-----------------------|----------------|------------------|--------------|--------------|-----------------------|----------------|
| Ochratoxin A | 5.0 | 20.0 | ND | 20 | Aflatoxin B1 | 2.5 | 5.0 | ND | - |
| Aflatoxin B2 | 2.5 | 5.0 | ND | - | Aflatoxin G1 | 2.5 | 5.0 | ND | - |
| Aflatoxin G2 | 2.5 | 5.0 | ND | - | Total Aflatoxins | 10.0 | 20.0 | ND | 20 |







Brandon Starr, Lab Manager Wed, 05 Apr 2023 10:13:00 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1

Authorized Signature

Brandon Starr

SD230329-008 page 2 of 2

QA Testing

PES - Pesticides Screening Analysis

Analyzed Apr 04, 2023 | Instrument LC/MSMS GC/MSMS | Method SOP-003

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|-------------------------|-------------|-------------|----------------|---------------|-----------------------|-------------|-------------|----------------|---------------|
| Aldicarb | 0.0078 | 0.02 | ND | 0.0078 | Carbofuran | 0.01 | 0.02 | ND | 0.01 |
| Dimethoate | 0.01 | 0.02 | ND | 0.01 | Etofenprox | 0.02 | 0.1 | ND | 0.02 |
| Fenoxycarb | 0.01 | 0.02 | ND | 0.01 | Thiachloprid | 0.01 | 0.02 | ND | 0.01 |
| Daminozide | 0.01 | 0.03 | ND | 0.01 | Dichlorvos | 0.02 | 0.07 | ND | 0.02 |
| Imazalil | 0.02 | 0.07 | ND | 0.02 | Methiocarb | 0.01 | 0.02 | ND | 0.01 |
| Spiroxamine | 0.01 | 0.02 | ND | 0.01 | Coumaphos | 0.01 | 0.02 | ND | 0.01 |
| Fipronil | 0.01 | 0.1 | ND | 0.01 | Paclobutrazol | 0.01 | 0.03 | ND | 0.01 |
| Chlorpyrifos | 0.01 | 0.04 | ND | 0.01 | Ethoprophos (Prophos) | 0.01 | 0.02 | ND | 0.01 |
| Baygon (Propoxur) | 0.01 | 0.02 | ND | 0.01 | Chlordane | 0.04 | 0.1 | ND | 0.04 |
| Chlorfenapyr | 0.03 | 0.1 | ND | 0.03 | Methyl Parathion | 0.02 | 0.1 | ND | 0.02 |
| Mevinphos | 0.03 | 0.08 | ND | 0.03 | Abamectin | 0.03 | 0.08 | ND | 0.1 |
| Acephate | 0.02 | 0.05 | ND | 0.1 | Acetamiprid | 0.01 | 0.05 | ND | 0.1 |
| Azoxystrobin | 0.01 | 0.02 | ND | 0.1 | Bifenazate | 0.01 | 0.05 | ND | 0.1 |
| Bifenthrin | 0.02 | 0.35 | ND | 3 | Boscalid | 0.01 | 0.03 | ND | 0.1 |
| Carbaryl | 0.01 | 0.02 | ND | 0.5 | Chlorantraniliprole | 0.01 | 0.04 | ND | 10 |
| Clofentezine | 0.01 | 0.03 | ND | 0.1 | Diazinon | 0.01 | 0.02 | ND | 0.1 |
| Dimethomorph | 0.02 | 0.06 | ND | 2 | Etoxazole | 0.01 | 0.05 | ND | 0.1 |
| Fenpyroximate | 0.02 | 0.1 | ND | 0.1 | Flonicamid | 0.01 | 0.02 | ND | 0.1 |
| Fludioxonil | 0.01 | 0.05 | ND | 0.1 | Hexythiazox | 0.01 | 0.03 | ND | 0.1 |
| Imidacloprid | 0.01 | 0.05 | ND | 5 | Kresoxim-methyl | 0.01 | 0.03 | ND | 0.1 |
| Malathion | 0.01 | 0.05 | ND | 0.5 | Metalaxyl | 0.01 | 0.02 | ND | 2 |
| Methomyl | 0.02 | 0.05 | ND | 1 | Myclobutanil | 0.02 | 0.07 | ND | 0.1 |
| Naled | 0.01 | 0.02 | ND | 0.1 | Oxamyl | 0.01 | 0.02 | ND | 0.5 |
| Permethrin | 0.01 | 0.02 | ND | 0.5 | Phosmet | 0.01 | 0.02 | ND | 0.1 |
| Piperonyl Butoxide | 0.02 | 0.06 | ND | 3 | Propiconazole | 0.03 | 0.08 | ND | 0.1 |
| Prallethrin | 0.02 | 0.05 | ND | 0.1 | Pyrethrin | 0.05 | 0.41 | ND | 0.5 |
| Pyridaben | 0.02 | 0.07 | ND | 0.1 | Spinosad A | 0.01 | 0.05 | ND | 0.1 |
| Spinosad D | 0.01 | 0.05 | ND | 0.1 | Spiromesifen | 0.02 | 0.06 | ND | 0.1 |
| Spirotetramat | 0.01 | 0.02 | ND | 0.1 | Tebuconazole | 0.01 | 0.02 | ND | 0.1 |
| Thiamethoxam | 0.01 | 0.02 | ND | 5 | Trifloxystrobin | 0.01 | 0.02 | ND | 0.1 |
| Acequinocyl | 0.02 | 0.09 | ND | 0.1 | Captan | 0.01 | 0.02 | ND | 0.7 |
| Cypermethrin | 0.02 | 0.1 | ND | 1 | Cyfluthrin | 0.04 | 0.1 | ND | 2 |
| Fenhexamid | 0.02 | 0.07 | ND | 0.1 | Spinetoram J,L | 0.02 | 0.07 | ND | 0.1 |
| Pentachloronitrobenzene | 0.01 | 0.1 | ND | 0.1 | | | | | |

RES - Residual Solvents Testing Analysis

Analyzed Apr 04, 2023 | Instrument GC/FID with Headspace Analyzer | Method SOP-006

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|----------------------------|-------------|-------------|----------------|---------------|------------------------------|-------------|-------------|----------------|---------------|
| Propane (Prop) | 0.4 | 40.0 | ND | 5000.0 | Butane (But) | 0.4 | 40.0 | ND | 5000.0 |
| Methanol (Metha) | 0.4 | 40.0 | ND | 3000.0 | Ethylene Oxide (EthOx) | 0.4 | 0.8 | ND | 1.0 |
| Pentane (Pen) | 0.4 | 40.0 | ND | 5000.0 | Ethanol (Ethan) | 0.4 | 40.0 | ND | 5000.0 |
| Ethyl Ether (EthEt) | 0.4 | 40.0 | ND | 5000.0 | Acetone (Acet) | 0.4 | 40.0 | ND | 5000.0 |
| Isopropanol (2-Pro) | 0.4 | 40.0 | ND | 5000.0 | Acetonitrile (Acetonit) | 0.4 | 40.0 | ND | 410.0 |
| Methylene Chloride (MetCh) | 0.4 | 0.8 | 1.0 | 1.0 | Hexane (Hex) | 0.4 | 40.0 | ND | 290.0 |
| Ethyl Acetate (EthAc) | 0.4 | 40.0 | ND | 5000.0 | Chloroform (Clo) | 0.4 | 0.8 | ND | 1.0 |
| Benzene (Ben) | 0.4 | 0.8 | ND | 1.0 | 1-2-Dichloroethane (12-Dich) | 0.4 | 0.8 | ND | 1.0 |
| Heptane (Hep) | 0.4 | 40.0 | ND | 5000.0 | Trichloroethylene (TriClEth) | 0.4 | 0.8 | ND | 1.0 |
| Toluene (Toluene) | 0.4 | 40.0 | ND | 890.0 | Xylenes (Xyl) | 0.4 | 40.0 | ND | 2170.0 |

FVI - Filth & Foreign Material Inspection Analysis

Analyzed Mar 30, 2023 | Instrument Microscope | Method SOP-010

| Analyte / Limit | Result | Analyte / Limit | Result |
|--|--------|---|--------|
| >1/4 of the total sample area covered by sand, soil, cinders, or dirt | ND | > 1/4 of the total sample area covered by mold | ND |
| >1 insect fragment, 1 hair, or 1 count mammalian excreta per 3g | ND | > 1/4 of the total sample area covered by an imbedded foreign material | ND |

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Wed, 05 Apr 2023 10:13:00 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "os received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evolution unless explicitude, state or local laws which are required by the nor Pass/Fail status is reported, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is available uncertainty is ava